Immunoglobulin A NephropathyDrugPhase 3
What this study is
The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of povetacicept in participants with immunoglobulin A nephropathy (IgAN).
What's being tested
- Povetacicept
Intervention · DRUG
Subcutaneous injection administration.
Study details
- Official title
- A Phase 3, Single-Arm, Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Conditions
- Immunoglobulin A Nephropathy
- Enrolling
- 605 people
- Starts
- 2026-09-17
- Est. completion
- 2029-12-28
- Design
- Open-label, single group, Phase 3
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Completed the Week 104 visit in the parent study VX24-AIS-D08 (NCT06564142) and has not permanently discontinued study drug
- Estimated glomerular filtration rate (eGFR) greater than or equal to (≥) 15 milliliters per minute (mL/min)/1.73 square meter (m^2) within 45 days of Day 1 of this study
You can't join if
- Planned participation in another interventional, therapeutic clinical trial (other than the parent study).
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (4)
4 openWestern Nephrology - Arvada
Arvada, Colorado, United States
CTR Oakwater, LLC
Orlando, Florida, United States
Idaho Kidney Institute- Idaho Falls
Idaho Falls, Idaho, United States
Prolato Clinical Research Center - Kirby Dr
Houston, Texas, United States
Study team
Sponsor
Vertex Pharmaceuticals Incorporated
Study ID VX25-AIS-102
Have questions? The record lists no central contact. Use Consider me and the site team can reach you, or find them through ClinicalTrials.gov ↗.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.